Completed PHASE2 INTERVENTIONAL 1-arm NCT00794716

PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)

Prospective Single-centre, Open-label Study to Assess the Pharmacokinetics of Cholyl-lysl-fluorescein (NRL972) in Patients with Clinical Evidence for NAFLD: Supporting the Disease Staging Into Fatty Liver Disease Versus NASH

Sponsor: Norgine

Conditions Non-Alcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis

Interventions NRL972

Updated 7 times since 2017 Last updated: Sep 9, 2024 Started: Jun 30, 2008 Primary completion: Mar 31, 2010 Completion: Nov 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-Alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, this trial is completed. The trial is conducted by Norgine and has accumulated 7 data snapshots since 2008. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Oct 2024 — Present [monthly]

Completed PHASE2
Sep 2024 — Oct 2024 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Norgine

Data source: Norgine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durham, United States